Return to search

Sheridan backs medical device company RSA

RSA's founding team will retain a "meaningful" ownership stake in the business,

  • RSA was founded in 1995 by Carl Hill and Kenneth Wolff
  • Kroll Inc served as financial advisor to RSA on the deal
  • RSA specializes in support services needed to maintain radiotherapy equipment used to treat cancer patients, most notably medical linear accelerators

Sheridan Capital Partners has made an investment in RS&A LLC, a Rural Hall, North Carolina-based medical device provider. No financial terms were disclosed.

Sheridan invested alongside RSA’s founding team, who will retain a “meaningful” ownership stake in the business and remain active in company operations.

Founded in 1995 by Carl Hill and Kenneth Wolff, RSA specializes in support services needed to maintain radiotherapy equipment used in the treatment of cancer patients, most notably medical linear accelerators.

On the partnership with Sheridan, DJ Conrad, CEO at RSA, said in a public statement: “The entire RSA leadership team and I are excited for the next chapter of growth in partnership with Sheridan. Sheridan’s investment and healthcare expertise will amplify our ability to deliver responsive, professional, and high-quality services to our valued clients and help improve patient care.”

McGuire Woods LLP served as legal counsel to Sheridan while Kroll Inc. served as financial advisor to RSA.

Sheridan Capital Partners is a Chicago-based healthcare private equity firm that focuses on lower middle market buyouts and growth equity in the U.S. and Canada.